MIMEDX GROUP INC (MDXG)

Company Profile

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 867 full-time employees. The company went IPO on 2007-08-20. The firm is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. The firm is focused on addressing unmet clinical needs in the areas of Advanced Wound Care, Surgical Recovery, and osteoarthritis. The firm operates through two segments: Wound and Surgical, and Regenerative Medicine. The Wound and Surgical segment focuses on the Advanced Wound Care and Surgical Recovery markets. Its platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc. The Regenerative Medicine segment focuses solely on Regenerative Medicine technologies. The Company’s product portfolio and pipeline include EPIFIX, AMNIOFIX, mDHACM, AMNIOBURN, EPICORD and AMNIOCORD, AXIOFILL, and AMNIOEFFECT.

Company Info

MIMEDX GROUP INC

1775 W Oak Commons Court, Ne

Marietta GEORGIA 30062

P: 17706519100

CEO: Timothy R. Wright

Employees: 867

Website: https://mimedx.com/